Boston Scientific Corporation
300 Boston Scientific Way
Marlborough
Massachusetts
01752
United States
Tel: (800) 876-9960
Website: http://www.bostonscientific.com/
1631 articles about Boston Scientific Corporation
-
Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon
3/1/2024
Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB).
-
Boston Scientific Announces Pricing of €2.0 Billion of Senior Notes
2/23/2024
Boston Scientific Corporation announced that American Medical Systems Europe B.V., its wholly owned finance subsidiary, has priced a public offering of €750,000,000 aggregate principal amount of 3.375% notes due 2029 and €1,250,000,000 aggregate principal amount of 3.500% notes due 2032.
-
Boston Scientific to Participate in TD Cowen's 44th Annual Health Care Conference
2/5/2024
Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 44th Annual Health Care Conference on Wednesday, March 6, 2024.
-
Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
1/31/2024
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period.
-
Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System
1/31/2024
Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System.
-
United Digestive Implements Innovative Education Program from Boston Scientific
1/11/2024
United Digestive has introduced a personalized education program powered by Boston Scientific.
-
Boston Scientific Announces Agreement to Acquire Axonics, Inc.
1/8/2024
Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Axonics, Inc., a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.
-
Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
1/8/2024
Axonics, Inc. announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation for $71 in cash per share, representing an equity value of approximately $3.7 billion.
-
Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
1/5/2024
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the fourth quarter ended December 31, 2023 , on Wednesday, January 31, 2024 , at 8:00 a.m. ET.
-
Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation
12/28/2023
Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation System* as a first-line treatment for persistent atrial fibrillation, the only trial to study the use of PFA as frontline therapy in patients with this form of AF.
-
Boston Scientific Closes Acquisition of Relievant Medsystems, Inc.
11/17/2023
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Relievant Medsystems Inc.
-
Boston Scientific to Participate in Stifel's 2023 Healthcare Conference
11/1/2023
Boston Scientific Corporation (NYSE: BSX) will participate in Stifel's 2023 Healthcare Conference on Tuesday, November 14, 2023.
-
Boston Scientific Announces Results for Third Quarter 2023
10/26/2023
Boston Scientific Corporation generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational1 basis and 10.2 percent on an organic2 basis, all compared to the prior year period.
-
Boston Scientific AGENT™ Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial
10/25/2023
Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal AGENT IDE clinical trial of the AGENT™ Drug-Coated Balloon (DCB).
-
REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of Pulmonary Embolism
10/24/2023
Data from the REAL-PE study was presented at TCT, the annual scientific symposium of the Cardiovascular Research Foundation, demonstrating that patients treated for pulmonary embolism with the Boston Scientific EKOS™ Endovascular System had lower rates of adverse events, including statistically significant lower rates of major bleeding, within seven days following their procedure compared to the Inari FlowTriever® System.
-
Boston Scientific Announces Conference Call Discussing Third Quarter 2023 Results
10/2/2023
Boston Scientific Corporation will webcast its conference call discussing financial results and business highlights for the third quarter ending September 30, 2023, on Thursday, October 26, 2023, at 8:00 a.m. EDT.
-
Boston Scientific Announces Agreement to Acquire Relievant Medsystems, Inc.
9/19/2023
Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company.
-
Boston Scientific Announces FDA Approval for the Latest-Generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device
9/6/2023
Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration approval for the latest-generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device.
-
Boston Scientific Announces 2023 Investor Day Meeting and Conference Call Discussing Third Quarter 2023 Results
9/5/2023
Boston Scientific Corporation (NYSE: BSX) will host a meeting with the investor community to review its financial goals and long-term growth strategies on Wednesday, September 20, 2023, between 8:30 a.m. and 1:00 p.m. ET.
-
ADVENT Study of the FARAPULSE™ Pulsed Field Ablation System Meets Primary Efficacy and Safety Endpoints
8/27/2023
Boston Scientific Corporation announced positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE™ Pulsed Field Ablation System*, a nonthermal treatment in which electric fields selectively ablate heart tissue in patients with atrial fibrillation.